EDAP TMS SA
corporate_fare Company Profile
EDAP TMS SA (NASDAQ:FOCL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for FOCL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for FOCL spans 10-Q, 8-K, 424B5.
Recent high-impact activity:
- Q3 Loss Narrower Than Expected at 4 Cents, But Revenue Drops 39% and Misses
- FocalTherics Q3 Revenue Up 26% to $9.8M; Cash Jumps to $56.3M After $42.4M Raise
- FocalTherics Q3 Revenue Up 26% to $9.8M; 2026 Guidance Narrowed to $50-52M
- Q3 Revenue Up 26% to $9.8M, But Guidance Range Trimmed at Top End
- Underwriters' Full Option Exercise Lifts EDAP TMS Offering by 15%
Financial Snapshot
Short Interest & Short Volume
9.37 days to coverFINRA reported short interest of 365,242 shares in FOCL as of the October 30, 2026 settlement, a 9.1% increase from the prior period — about 9.4 days to cover at its recent average daily volume. On November 19, 2026, 53.8% of FOCL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for FOCL, detected from its recent SEC filings · based on capital-structure filings through 2026-08-12.
Offering Priced at $4.75/ADS · Significant Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →